Head-To-Head Review: Catalent (CTLT) versus Its Peers

Catalent (NYSE: CTLT) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Catalent to related businesses based on the strength of its dividends, earnings, institutional ownership, valuation, profitability, analyst recommendations and risk.

Analyst Ratings

This is a summary of recent recommendations for Catalent and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 2 6 0 2.75
Catalent Competitors 879 3824 6806 181 2.54

Catalent currently has a consensus price target of $44.00, indicating a potential upside of 9.84%. As a group, “Pharmaceuticals” companies have a potential upside of 22.40%. Given Catalent’s rivals higher probable upside, analysts clearly believe Catalent has less favorable growth aspects than its rivals.

Risk and Volatility

Catalent has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Catalent’s rivals have a beta of 34.66, indicating that their average stock price is 3,366% more volatile than the S&P 500.

Insider and Institutional Ownership

99.5% of Catalent shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Catalent shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Catalent and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 5.01% 23.97% 5.24%
Catalent Competitors -2,402.47% -68.58% -7.25%

Earnings and Valuation

This table compares Catalent and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catalent $2.08 billion $109.80 million 46.05
Catalent Competitors $8.17 billion $1.09 billion 145.98

Catalent’s rivals have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Catalent rivals beat Catalent on 7 of the 13 factors compared.

About Catalent

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply